Advanced NSCLC: FDA approves atezolizumab plus chemotherapy


  • Kelli Whitlock Burton
  • Oncology drug update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The US FDA has approved atezolizumab in combination with paclitaxel protein-bound and carboplatin for first-line treatment of adults with metastatic NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations.

Why this matters

  • Atezolizumab was first approved in 2016 in NSCLC patients with disease progression after treatment with platinum-based chemotherapy, and then in 2018 for first-line treatment in advanced NSCLC in combination with bevacizumab, paclitaxel, and carboplatin.
  • EMA information on atezolizumab indications, including NSCLC, is available here.

Key points

  • Recommended dosage 1200 mg/20 mL (60 mg/mL) by intravenous infusion every 3 weeks.
  • Approval based on study results of the multicenter, randomized, open-label, phase 3 IMpower130 trial.
    • 681 patients receive atezolizumab, paclitaxel protein-bound, and carboplatin, followed by single-agent atezolizumab or paclitaxel protein-bound and carboplatin, followed by maintenance pemetrexed (control).
    • Median PFS was 7.2 months with atezolizumab vs 6.5 months in the control group (HR, 0.75; P=.0024).
    • Median OS was 18.6 months with atezolizumab vs 13.9 months in the control group (HR, 0.80; P=.0384).
  • Most common adverse events when administered in combination with other antineoplastic drugs in patients with NSCLC and small-cell lung cancer were fatigue/asthenia, nausea, alopecia, constipation, diarrhea, and decreased appetite.

For prescribing information, click here.